12-Month Analysis of ILLUMINATE-A, a Phase 3 Study of Lumasiran: Sustained Oxalate Lowering and Kidney Stone Event Rates in Primary Hyperoxaluria Type 1
Journal of the American Society of Nephrology | May 17, 2024 | Volume: 31 | Issue: 10S | Pages: B8-B8
10.1681/asn.20203110s1b8c